tert-butyl 4-(1-(phenylsulfonyl)-1H-indol-3-yl)piperidine-1-carboxylate | 855776-16-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-(1-(phenylsulfonyl)-1H-indol-3-yl)piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-[1-(benzenesulfonyl)indol-3-yl]piperidine-1-carboxylate
• CAS: 855776-16-8
• 化学式: C₂₄H₂₈N₂O₄S
• 分子量: 440.563
• InChiKey: OXQZPQSANYFUIU-UHFFFAOYSA-N

物化性质

• 沸点：
  607.7±65.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  77
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(1-(phenylsulfonyl)-1H-indol-3-yl)piperidine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 1-Benzenesulfonyl-3-piperidin-4-yl-1H-indole
  参考文献：
  名称：

  N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists

  摘要：

  A series of Ni-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)indole derivatives was designed and synthesized. These compounds were shown to have high affinity for the 5-HT6 receptor. Two analogs, 4-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-1-sulfonyl]-phenylamine 15g and 4-[3-(1,2,3,6-tetrahydropyridin-4-yl)-5-methoxy-1H-indole-1-sulfonyl]-phenylamine 15y, had 0.4 and 3.0nM affinity, respectively, and antagonized the production of adenylate cyclase at sub-nanomolar concentrations. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.064
• 作为产物：
  描述：

  吲哚 在 palladium on activated charcoal 氢氧化钾 、 potassium tert-butylate 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 生成 tert-butyl 4-(1-(phenylsulfonyl)-1H-indol-3-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists

  摘要：

  A series of Ni-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)indole derivatives was designed and synthesized. These compounds were shown to have high affinity for the 5-HT6 receptor. Two analogs, 4-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-1-sulfonyl]-phenylamine 15g and 4-[3-(1,2,3,6-tetrahydropyridin-4-yl)-5-methoxy-1H-indole-1-sulfonyl]-phenylamine 15y, had 0.4 and 3.0nM affinity, respectively, and antagonized the production of adenylate cyclase at sub-nanomolar concentrations. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.064

文献信息

• [EN] INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES<br/>[FR] DERIVES D'INDOLE POUR LE TRAITEMENT DE MALADIES DES OS
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2005056012A1

  公开（公告）日：2005-06-23

  This invention relates to a method for preventing and/or treating bone diseases which comprises administering a potentiator of TGF-beta activity such as the compound of the formula [I] or pharmaceutically acceptable salts thereof to human being or animals. wherein R1 is hydrogen, etc., R2 is optionally substituted ar(lower)alkyl or optionally substituted heterocyclic(lower)alkyl, etc., R3 is hydrogen, optionally substituted hydroxy, etc., R4 is hydrogen or lower alkyl, and X is CH or N.

  这项发明涉及一种用于预防和/或治疗骨疾病的方法，包括向人类或动物施用TGF-beta活性增强剂，如式[I]的化合物或其药用盐。其中R1是氢，R2是可选择取代的芳基(较低)烷基或可选择取代的杂环(较低)烷基，R3是氢，可选择取代的羟基，R4是氢或较低烷基，X是CH或N。
• Highly Selective Palladium-Catalyzed Cross-Coupling of Secondary Alkylzinc Reagents with Heteroaryl Halides
  作者：Yang Yang、Katrin Niedermann、Chong Han、Stephen L. Buchwald

  DOI：10.1021/ol502230p

  日期：2014.9.5

  The highly selective palladium-catalyzed Negishi coupling of secondary alkylzinc reagents with heteroaryl halides is described. The development of a series of biarylphosphine ligands has led to the identification of an improved catalyst for the coupling of electron-deficient heterocyclic substrates. Preparation and characterization of oxidative addition complex (L)(Ar)PdBr provided insight into the

  描述了仲烷基锌试剂与杂芳基卤化物的高选择性钯催化 Negishi 偶联。一系列联芳基膦配体的开发导致鉴定出一种用于缺电子杂环底物偶联的改进催化剂。氧化加成配合物 ( L )(Ar)PdBr 的制备和表征提供了洞察基于 CPhos 型配体的催化剂在促进具有挑战性的还原消除过程中的独特反应性。
• New methods
  申请人：Takeshita Nobuaki

  公开号：US20050245540A1

  公开（公告）日：2005-11-03

  This invention relates to a method for preventing and/or treating bone diseases which comprises administering a potentiator of TGF-beta activity such as the compound of the formula [I] or pharmaceutically acceptable salts thereof to human being or animals. wherein R 1 is hydrogen, etc., R 2 is optionally substituted ar(lower)alkyl or optionally substituted heterocyclic(lower)alkyl, etc., R 3 is hydrogen, optionally substituted hydroxy, etc., R 4 is hydrogen or lower alkyl, and X is CH or N.

  本发明涉及一种预防和/或治疗骨疾病的方法，该方法包括向人类或动物施用TGF-beta活性增强剂，例如式[I]化合物或其药学上可接受的盐。其中，R1为氢等，R2为可选取代的芳基（较低）烷基或可选取代的杂环（较低）烷基等，R3为氢、可选取代的羟基等，R4为氢或较低烷基，X为CH或N。
• Effects of chronic mild stress on rats selectively bred for behavior related to bipolar disorder and depression
  作者：Ryan Murray、Katherine A. Boss-Williams、Jay M. Weiss

  DOI：10.1016/j.physbeh.2013.05.042

  日期：2013.7

  To test the possibility that chronic mild stress (CMS) might be unreliable in producing its often-intended outcome (i.e., decreased preference for sucrose, hypothesized to represent depression-relevant anhedonia) because it is typically applied to "normal" rats, a CMS procedure was applied to rats that may possess genetic susceptibility to affective disorders, having had been selectively-bred to show behavior indicative of such disorders. These rat lines were: Hyperactive (HYPER) rats, which show characteristics of bipolar disorder, Swim-test Susceptible (SUS) and Swim-test Resistant (RES) rats, being susceptible or resistant to effects of stress in the swim test, Swim High-active (SwHi) and Swim Low-active (SwLo) rats, which innately show high or low activity in the swim test These selectively-bred lines were compared to normal, non-selectively bred (NS) rats. During CMS, HYPER rats, both females and males, as well as RES and SwHi rats, showed reduced consumption of a palatable 2% sucrose solution, and reduced preference for sucrose (vs. water) in comparison to non-stressed rats (no CMS) of the same lines. In contrast, CMS produced no decrease in sucrose consumption or in preference for sucrose in normal NS rats, and actually a caused a slight increase in sucrose consumption and preference in male NS rats. Other measures that indicate depression - food intake and motor activity in the home cage - were also assessed. SwLo and SwHi showed greater sensitivity to having their home-cage ambulatory activity reduced by CMS than did NS rats, but no other such differences relative to NS rats were seen for these other measures; thus, changes in sucrose intake or preference could not be explained by a change in caloric intake. These results suggest that the genetic attributes of animals can influence the outcome of CMS, and that the application of CMS to normal, non-selected rats may account, at least in part, for the unreliability of CMS in decreasing consumption of palatable substances and decreasing preference for such substances. (C) 2013 Published by Elsevier Inc.
• INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES
  申请人：Astellas Pharma Inc.

  公开号：EP1691807A1

  公开（公告）日：2006-08-23